As soon as patent expiries, biopharmaceuticals can be produced and marketed by manufacturers other than the originator. These new biotechnology medicines are known as “biosimilars” or “similar biological medicinal products” because they are claimed to be highly similar to an already approved reference product.

According to the European regulatory framework, biosimilarity means that the biological product is highly similar to the licensed reference biological product notwithstanding minor differences in clinically inactive components; and that there are no clinically meaningful differences between the biologic product and the reference product in terms of the safety, purity, and potency of the product.

In 2006, the first biosimilars have received European regulatory approval, therefore becoming a commercial reality in European markets.

  • Insuline: The first product to be launched will be Insulin Glargine used for diabetic patients. Agroaxis has successfully overcome the first stages of Research and Development and plans to go into Preclinical stage in mid 2015.
  • EPO: Erythropoietin (also known as EPO) is a hormone produced largely in the kidneys that influences the rate of red blood cells production, increasing or decreasing it in accordance with need.


Nutraceuticals and Medicinal Plants

Historically, mankind is closely linked with the use of medicinal plants to cure illnesses and ailments. Today, the evidence shows that synthetic drugs cause negative side effects, stimulating the consumption of natural products and that includes nutraceuticals.

Regarding nutraceuticals and medicinal plants, they are increasingly seen as part of a healthier and more sustainable lifestyle, in line with a trend on health products based more on prevention rather than cure.


More on Agroaxis

The advances in molecular biology and more particularly recombinant DNA technology has allowed nutritionally valuable products, healthcare and industry , can be produced in large quantities at low cost and with increased biosafety.
The idea of using plant systems for the production of recombinant proteins has ceased to be a challenge to become a reality and alternative for the biopharmaceutical industry.

AGROAXIS decided to use and adapt the System NGS® to all their technology platforms to respond to the growing need of a new culture technologies and as a result of water scarcity and soil low yields increasingly overexploited.

Latest News

  • Agroaxis hires three more technologists with the grant Inncorpora TU of the Ministry of Economy and Competitiveness
  • Agroaxis creates the first GreenMab® technology platform with plants Snuff “Human “Insulin for obtaining

    Copyright 2013 Agroaxis. All Rights Reserved